SCHEMBL4394735

SCHEMBL4394735

COC(=O)Cc1cccc(CCc2cccc(CC(=O)OC)c2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.62
CYP4F2 P78329 4/20 0.55
CYP4A11 Q02928 4/20 0.55
HSP90AB1 P08238 1/20 0.53
ALDH1A1 P00352 2/20 0.53
GAA P10253 1/20 0.53
GFER P55789 1/20 0.53
HPGD P15428 3/20 0.49
MAPT P10636 1/20 0.49
TSHR P16473 1/20 0.49
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.44
PDK2 Q15119 1/20 0.44
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
NFKB1 P19838 1/20 0.44
RAB9A P51151 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12400239 0.94 SLC7A5 (0.68) SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1
SCHEMBL28655132 0.91 SLC7A5 (0.57) SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1
SCHEMBL8427611 0.91 CYP4F2 (0.69) SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1
SCHEMBL14420123 0.91 SLC7A5 (0.57) SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1
SCHEMBL30559747 0.90 SLC7A5 (0.60) SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1
SCHEMBL27649231 0.90 SLC7A5 (0.56) SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1
SCHEMBL6581681 0.90 SLC7A5 (0.60) SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1
Iodide SCHEMBL5949324 0.90 SLC7A5 (0.56) SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1
SCHEMBL3013114 0.88 CHRM2 (0.57) SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1
Iodide SCHEMBL5949320 0.88 SLC7A5 (0.55) SLC7A5CYP4F2CYP4A11HSP90AB1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 US disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 SLC7A5 176/4885CYP4F2 399/4885CYP4A11 489/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A SLC7A5 4227/4885CYP4F2 639/4885CYP4A11 938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.